Clinical trial

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

NCT03130764

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Durvalumab Normalized identity: durvalumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Tremelimumab Normalized identity: tremelimumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2017-03-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

TremelimumabDRUG · verified · RxNorm: tremelimumab

Sponsors & collaborators

Columbia Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03130764 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.